Search - tctmd.com

Displaying 61 - 80 of 299

Sort: Relevancy | Date

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Percutaneous Left Atrial Appendage Closure Versus Chronic Oral Anticoagulation for Non-Valvular Atrial Fibrillation: An Individual Patient Data Level Meta-Analysis of Randomized Controlled Trials

Presentation TCT 2023

Percutaneous Left Atrial Appendage Closure Versus Chronic Oral Anticoagulation for Non-Valvular Atrial Fibrillation: An Individual Patient Data Level Meta-Analysis of Randomized Controlled Trials

Presenter: Yousif Ahmad

October 25, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

One-Third of Patients With AF After Surgery or Illness Have Recurrences

News Daily News

One-Third of Patients With AF After Surgery or Illness Have Recurrences

Michael O'Riordan

October 02, 2023

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

September 18, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

What’s Going to Be Hot at ESC 2023?

News Opinion Editor's Corner ESC 2023

What’s Going to Be Hot at ESC 2023?

August 15, 2023

Off-label DOAC Dosing Tied to Worse Adherence, More Discontinuation

News Daily News

Off-label DOAC Dosing Tied to Worse Adherence, More Discontinuation

June 14, 2023

Low Dose Direct Oral Anticoagulation vs. DAPT after LAAO - ADALA Trial

Presentation EuroPCR 2023

Low Dose Direct Oral Anticoagulation vs. DAPT after LAAO - ADALA Trial

Presenter: Xavier Freixa

May 17, 2023

SCAI/HRS Consensus Document Covers the Ins and Outs of LAAO

News Daily News

SCAI/HRS Consensus Document Covers the Ins and Outs of LAAO

March 28, 2023

Acute AF Can Recur: Manage and Monitor Long-term, Says AHA

News Daily News

Acute AF Can Recur: Manage and Monitor Long-term, Says AHA

Michael O'Riordan

March 16, 2023

LAAO Tops Oral Anticoagulation for AF in Women and Men: Medicare Analysis

News Daily News

LAAO Tops Oral Anticoagulation for AF in Women and Men: Medicare Analysis

February 24, 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

News Conference News ISC 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

February 17, 2023

Continuous Monitoring Finds AF Up to 3 Years After Noncryptogenic Stroke

News Conference News ISC 2023

Continuous Monitoring Finds AF Up to 3 Years After Noncryptogenic Stroke

February 08, 2023

Top Heart Rhythm News of 2022

News Daily News

Top Heart Rhythm News of 2022

January 05, 2023

Left Atrial Dysfunction Tied to Cerebral Infarcts in Absence of Prior AF, Stroke

News Daily News

Left Atrial Dysfunction Tied to Cerebral Infarcts in Absence of Prior AF, Stroke

December 21, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.